{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Climara&page=21",
    "query": {
      "intervention": "Climara",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 887,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Climara&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Climara&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T07:03:12.401Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00781456",
      "title": "A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "91-day Levonorgestrel Oral Contraceptive",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duramed Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 34 Years · Female only"
      },
      "enrollment_count": 109,
      "start_date": "2009-01",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2017-02-06",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 22,
      "location_summary": "La Mesa, California • San Diego, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00781456"
    },
    {
      "nct_id": "NCT06071442",
      "title": "Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Vemircopan",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Levonorgestrel / Ethinyl Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-01-17",
      "completion_date": "2024-04-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06071442"
    },
    {
      "nct_id": "NCT07784582",
      "title": "Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Turner Syndrome",
        "Primary Ovarian Insufficiency"
      ],
      "interventions": [
        {
          "name": "Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "12 Years",
        "sex": "FEMALE",
        "summary": "8 Years to 12 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2026-09-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07784582"
    },
    {
      "nct_id": "NCT05759949",
      "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PIK3CA Mutation",
        "Solid Tumor, Adult",
        "HER2-negative Breast Cancer",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Unresectable Solid Tumor",
        "Hormone Receptor Positive Tumor"
      ],
      "interventions": [
        {
          "name": "RLY-5836",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2023-03-29",
      "completion_date": "2025-04-11",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 7,
      "location_summary": "Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05759949"
    },
    {
      "nct_id": "NCT00217464",
      "title": "Fulvestrant in Treating Patients With Recurrent Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 17,
      "start_date": "2004-06",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2015-04-16",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217464"
    },
    {
      "nct_id": "NCT07558733",
      "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HR+ HER2- Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Serabelisib",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faeth Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-04-22",
      "completion_date": "2033-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07558733"
    },
    {
      "nct_id": "NCT07811232",
      "title": "A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Neoplasms",
        "Soft Tissue Sarcoma (STS)",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "AL58805",
          "type": "DRUG"
        },
        {
          "name": "AL8326",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advenchen Pharmaceuticals, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-09-01",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07811232"
    },
    {
      "nct_id": "NCT00357604",
      "title": "Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)",
          "type": "DRUG"
        },
        {
          "name": "Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2006-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2011-04-08",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357604"
    },
    {
      "nct_id": "NCT07739589",
      "title": "A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Residual Drug Amount of EE and LNG"
      ],
      "interventions": [
        {
          "name": "Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insud Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2021-10-25",
      "completion_date": "2021-11-16",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07739589"
    },
    {
      "nct_id": "NCT03856268",
      "title": "Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Menopause Surgical",
        "Estrogen Deficiency",
        "Adiposity",
        "Follicle-Stimulating Hormone Deficiency",
        "Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "'Surgical Menopause' Group",
          "type": "PROCEDURE"
        },
        {
          "name": "'Drug-Induced Menopause' Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2019-04-01",
      "completion_date": "2022-11-11",
      "has_results": false,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-10-24T07:03:12.401Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03856268"
    }
  ]
}